Revision of the Histopathological Examination Following <sup>68</sup>Ga-DOTA-FAPI-04 PET/CT of a Breast Tumor Diagnosed as Invasive Ductal Carcinomatosis
PDF
Cite
Share
Request
Case Report
P: 134-137
June 2024

Revision of the Histopathological Examination Following 68Ga-DOTA-FAPI-04 PET/CT of a Breast Tumor Diagnosed as Invasive Ductal Carcinomatosis

Mol Imaging Radionucl Ther 2024;33(2):134-137
1. Yeditepe University Faculty of Medicine Department of Nuclear Medicine, İstanbul, Türkiye
2. Yeditepe University Faculty of Medicine Department of Medical Oncology, İstanbul, Türkiye
3. İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Türkiye
No information available.
No information available
Received Date: 15.06.2023
Accepted Date: 01.01.2024
Online Date: 28.06.2024
Publish Date: 28.06.2024
PDF
Cite
Share
Request

ABSTRACT

Neuroendocrine tumors (NETs) of the breast represent 1% of breast carcinomas. Histopathological misinterpretation of breast NET is common. We present the case of a female patient who had a breast mass diagnosed as invasive ductal carcinoma initially by histopathological examination. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) revealed 2 ametabolic hypodense liver lesions. Subsequently, the patient underwent fibroblast activation protein inhibitor (FAPI)-PET/CT, which did not reveal any FAP expression in the liver lesions, but increased FAP expression was observed in the soft tissue mass of the mesenteric root. Consequently, the pathology of the biopsy taken from the nodule in the right breast was revised, and a diagnosis of grade 2 NET was established. The benefit of FAPI-PET/CT on NETs has been previously investigated. Further prospective studies are required to establish the role of FAPI-PET/CT in NET management

Introduction

Metastatic neuroendocrine tumors (NETs) are exceedingly rare in breast cancer, representing less than 1% of all breast carcinomas (1,2). A study examining 18 cases of NETs metastasizing to the breast revealed that 62% of these tumors originated from the gastrointestinal tract and 28% from the lungs. Notably, 44% of these tumors were initially misdiagnosed as primary breast carcinoma (1). We present a rare case of metastatic NET initially reported as invasive ductal carcinoma (IDC), which was demonstrated through [68Ga]gallium-fibroblast activation protein inhibitor (68Ga-FAPI) positron emission tomography/computed tomography (PET/CT) and [68Ga]Ga-DOTATATE PET/CT imaging.

Case Report

A 59-year-old female patient presented with a 1-year history of nausea, vomiting, and flushing. During a physical examination, a breast mass was detected, which led to a tru-cut biopsy. Histopathological analysis initially indicated IDC (Figure 1). She was subsequently referred to our clinic for staging. Fluorodeoxyglucose (FDG) PET/CT revealed a slightly hypermetabolic 7-mm nodule in the right breast and two hypodense, ametabolic liver lesions (Figure 2A). Considering the ametabolic nature of these liver lesions, lobular carcinoma was suspected, prompting [68Ga]Ga-DOTA-FAPI-04 PET/CT. This imaging did not demonstrate any FAP expression in the liver lesions, but increased FAP expression was observed in the mesenteric root soft tissue mass and right breast nodular lesion (Figure 2B). Maximum standardized uptake value of uptake in the mesenteric root was 16. Upon retrospective re-evaluation of the patient’s clinical findings, the mesenteric root soft tissue mass, as demonstrated by [68Ga]Ga-DOTA-FAPI-04 PET/CT, along with symptoms such as nausea, vomiting, and flushing, were consistent with a diagnosis of NET. Based on these findings, the histopathological examination was repeated, and the diagnosis was revised to NET (Figure 3). In addition to revising the primary pathological sample, histopathological examination of biopsies obtained from the mesentery and liver confirmed the diagnosis of grade 2 NET. Consequently, [68Ga]Ga-DOTATATE PET/CT was performed. Imaging revealed a soft tissue mass in the mesenteric root with increased somatostatin receptor (SSTR) expression, multiple SSTR-positive bone, liver, and lymph node metastases, and metastatic SSTR-positive nodules in both breasts (Figure 2C).

Informed consent was obtained from the patient for all modalities.

Literature Review and Discussion

Although the FAPI uptake pattern of NETs is not exactly established, heterogeneous uptake has been reported (3). In addition to that, [68Ga]Ga-FAPI PET/CT’s utility in primary and metastatic NETs was previously demonstrated in case reports (4,5,6,7). Despite the high FAP expression of the primary tumor (mass in mesenteric root) in our case, the absence of FAPI uptake by liver and bone metastases was remarkable. In this case, 18F-FDG PET/CT was requested for the preoperative staging of breast cancer. However, the 18F-FDG PET/CT scan revealed a mildly FDG-avid nodule in the right upper outer quadrant of the breast. In addition, soft tissue mass in the mesenteric root and hypodense nodules in the right hepatic lobe were FDG-negative. Concurrently, magnetic resonance imaging of the liver interpreted these liver nodules as suggestive of metastases. In the literature, there is a substantial amount of data suggesting that [68Ga]Ga-FAPI PET/CT, because of the absence of background liver activity, can better detect metastatic lesions (8). Therefore, we performed [68Ga]Ga-FAPI PET/CT to evaluate the possibility of lobular breast carcinoma and its metastasis in the liver. However, [68Ga]Ga-[68Ga]Ga-FAPI PET/CT images did not show uptake in the liver lesions. Instead, an additional FAPI-avid mass within the mesenteric root that was inseparable from the bowel loops was detected in the abdominal region, along with multiple metastatic nodules in both breast lobes, raising the suspicion that the primary tumor might not be in the breast but rather in the abdominal mass, possibly a NET. As a result, a biopsy was recommended to the lesion in the mesenteric root and revealed a diagnosis of G2 NET. Afterwards [68Ga]Ga-DOTATATE PET was performed for staging of NET. [68Ga]Ga-DOTATATE imaging revealed SSTR positivity in the breast, abdominal, and liver lesions. Additional multiple bone metastases were detected.

In this case, following these three imaging modalities, the patient’s clinical diagnosis and stage changed significantly. Initially referred to our clinic for preoperative staging of breast cancer, the patient was ultimately diagnosed with metastatic NET, leading to the initiation of systemic treatment. NET metastases in the breast are quite rare, and biopsy alone may not be sufficient. In such cases, molecular imaging techniques such as [68Ga]Ga-FAPI and [68Ga]Ga-DOTATATE can be beneficial.

The images of PET/CTs using 3 different tracers all showed multiple foci of increased uptake of radiopharmaceutical in the abdomen and breast, in which [68Ga]Ga-FAPI PET/CT displayed the highest tumor-to-background ratio. However, [68Ga]Ga-DOTATATE PET/CT detected more metastatic lesions and liver and bone metastases, which were missed by both 18F-FDG and [68Ga]Ga-FAPI PET/CT.

In this study, both modalities led to a complete change in the patient’s histopathological diagnosis and, concurrently, a shift in the treatment algorithm.

Ethics

Informed Consent: Informed consent was obtained from the patient for all modalities.

Authorship Contributions

Surgical and Medical Practices: N.A.S., S.Ç., B.B.Ö., Concept: N.A.S., S.Ç., B.B.Ö., L.K., Design: N.A.S., L.K., Data Collection or Processing: K.A., G.B., Ö.S., Analysis or Interpretation: N.A.S., L.K., Literature Search: K.A., G.B., Ö.S., Writing: N.A.S., K.A., G.B., Ö.S., S.Ç., B.B.Ö., L.K.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1
Dev S. Impact of natural products in modern drug development. Indian J Exp Biol. 2010;48:191-198.
2
El-Tarabily KA, El-Saadony MT, Alagawany M, Arif M, Batiha GE, Khafaga AF, Elwan HAM, Elnesr SS, E Abd El-Hack M. Using essential oils to overcome bacterial biofilm formation and their antimicrobial resistance. Saudi J Biol Sci. 2021;28:5145-5156.
3
Nett J, Andes D. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol. 2006;9:340-345.
4
Kou J, Xin TY, McCarron P, Gupta G, Dureja H, Satija S, Mehta M, Bakshi HA, Tambuwala MM, Collet T, Dua K, Chellappan DK. Going beyond antibiotics: natural plant extracts as an emergent strategy to combat biofilm-associated infections. J Environ Pathol Toxicol Oncol. 2020;39:125-136.
5
Wu H, Moser C, Wang HZ, Høiby N, Song ZJ. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7:1-7.
6
Cavalheiro M, Teixeira MC.Candida Biofilms: Threats, challenges, and promising strategies. Front Med (Lausanne). 2018;5:28.
7
Di Domenico EG, Oliva A, Guembe M. The current knowledge on the pathogenesis of tissue and medical device-related biofilm infections. Microorganisms. 2022;10:1259.
8
Taraszkiewicz A, Fila G, Grinholc M, Nakonieczna J. Innovative strategies to overcome biofilm resistance. Biomed Res Int. 2013;2013:150653.
9
Gürdal B, Kültür S. An ethnobotanical study of medicinal plants in Marmaris (Muğla, Turkey). J Ethnopharmacol. 2013;146:113-126.
10
Kültür S. Medicinal plants used in Kirklareli Province (Turkey). J Ethnopharmacol. 2007;111:341-364.
11
Nath EO. An ethnobotanical study in Savaştepe and Kepsut region (Balıkesir). PhD thesis. Istanbul University, Institute of Health Science, 2016.
12
Polat R, Satıl F. An ethnobotanical survey of medicinal plants in Edremit Gulf (Balıkesir-Turkey). J Ethnopharmacol. 2012;139:626-641.
13
Tuzlaci E, Aymaz PE. Turkish folk medicinal plants, Part IV: Gönen (Balikesir). Fitoterapia. 2001;72:323-343.
14
Emir A, Emir C, Yıldırım H. Chemical and biological comparison of different parts of twoAllium species: Allium paniculatum L. subsp. villosulum (Hal.) Stearn and Allium paniculatum L. subsp. paniculatum L. Chem Pap. 2021;75:411-419.
15
Özdemir Nath E, Kültür Ş. Wild edible plants of Savaştepe district (Balıkesir, Turkey). Marmara Pharm J. 2017;21:578-589.
16
Clinical and laboratory standards institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (7th ed). Approved standard M7-A7. Wayne, PA, USA; 2006.
17
Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing; (2nd) informational supplement. M100-S21. Wayne, PA, USA; 2011.
18
Abreu AC, McBain AJ, Simões M. Plants as sources of new antimicrobials and resistance-modifying agents. Nat Prod Rep. 2012;29:1007-1021.
19
Özdemir Nath E, Kültür Ş. An ethnobotanical study of medicinal plants in Savaştepe (Balıkesir-Turkey). Clin Exp Health Sci. 2022;12:954-980.
20
Kahraman C, Sari S, Küpeli Akkol E, Tatli Cankaya I. Bioactive saponins of primula vulgaris huds. promote wound healing through inhibition of collagenase and elastase enzymes:in vivo, in vitro and in silico evaluations. Chem Biodivers. 2022;19:e202200582.
21
Álvarez-Martínez FJ, Rodríguez JC, Borrás-Rocher F, Barrajón-Catalán E, Micol V. The antimicrobial capacity ofCistus salviifolius and Punica granatum plant extracts against clinical pathogens is related to their polyphenolic composition. Sci Rep. 2021;11:588.
22
Nur Onal F, Ozturk I, Aydin Kose F, Der G, Kilinc E, Baykan S. Comparative Evaluation of Polyphenol Contents and Biological Activities of Five Cistus L. Species Native to Turkey. Chem Biodivers. 2023;20:e202200915.
23
Küpeli E, Yesilada E. Flavonoids with anti-inflammatory and antinociceptive activity from Cistus laurifolius L. leaves through bioassay-guided procedures. J Ethnopharmacol. 2007;112:524-530.
24
Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015;34:877-886.
25
Barbu IA, Ciorîță A, Carpa R, Moț AC, Butiuc-Keul A, Pârvu M. Phytochemical characterization and antimicrobial activity of severalAllium extracts. Molecules. 2023;28: 3980.
26
Galdiero E, Di Onofrio V, Maione A, Gambino E, Gesuele R, Menale B, Ciaravolo M, Carraturo F, Guida M.Allium ursinum and Allium oschaninii against Klebsiella pneumoniae and Candida albicans Mono- and Polymicrobic Biofilms in in vitro static and dynamic models. Microorganisms. 2020;8:336.
27
Ng TS, Looi LJ, Ong BS, Chong PP. Antifungal and anti-biofilm effects of shallot (Allium ascalonicum) aqueous extract on Candida albicans. J Herbmed Pharmacol. 2018;7:236-242.
28
Lanzotti V, Scala F, Bonanomi G. Compounds fromAllium species with cytotoxic and antimicrobial activity. Phytochem Rev. 2014;13:769-791.
29
Mskhiladze L, Legault J, Lavoie S, Mshvildadze V, Kuchukhidze J, Elias R, Pichette A. Cytotoxic steroidal saponins from the flowers ofAllium leucanthum. Molecules. 2008;13:2925-2934.